Search Results - "Espinoza Peralta, Diego"

879-P: Cardiorenal Outcomes Associated with the Use of Dapagliflozin Compared with DPP-4 Inhibitors as Add-on Treatment in Uncontrolled DM2 Patients with Failure to Previous Treatment—A Retrospective, Real-Life Evaluation in México by ESPINOZA-PERALTA, DIEGO, HERNANDEZ-ALARCON, JIMENA, LOPEZ, IRLANDA N., CETINA-CANTO, JOSE, BÚRQUEZ-GONZÁLEZ, MARIA E., PAUL, PEDRO V., BUSTAMANTE, GUADALUPE A., CARLOS GARNICA CUELLAR, JUAN, MIRELES-ZAVALA, LEONOR G., JUAREZ-COMBONI, SONIA C., RODRÍGUEZ, ARELI M.

“…Mexico is one of the three countries in Region of Americas with the highest prevalence (14.4%) of DM. We conducted a retrospective study in Mexico and compare…”
Get full text

104-LB: Glucose-Insulin-Potassium (GIK) as a Proposed Treatment for Normoglycemic Diabetic Ketoacidosis: An Old Friend for a New Foe? by ESPINOZA-PERALTA, DIEGO, MONJARDIN-ROCHIN, JOSE ALFONSO, BÚRQUEZ-GONZÁLEZ, MARIA E., MIRELES-ZAVALA, LEONOR G.

“…Introduction: Glucose, Insulin, and potassium (GIK) infusions were introduced into medical practice to reduce myocardial injury during a heart attack in 1962…”
Get full text

Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial by Laffel, Lori M, Danne, Thomas, Klingensmith, Georgeanna J, Tamborlane, William V, Willi, Steven, Zeitler, Philip, Neubacher, Dietmar, Marquard, Jan, Bardymova, Tatiana, Barrientos Perez, Margarita, Bethin, Kathleen, Bjornstad, Petter, Bondar, Irina, Chen, Mimi, Choi, Jin-Ho, Clements, Mark A, Colomar, Javier Ricardo, Daniels, Mark, Deerochanawong, Chaicharn, Desai, Vivek S, Desmangles, Jean-Claude G, Dillon, Robert G, Dixit, Naznin M, Du, Hongwei, Edelen, Rachel, Espinoza Peralta, Diego, Felipe Gacioppo, María Verónica, Ferraz, Tania Maria Bulcão Lousada, Galkina, Galina, Gallagher, Mary Patricia, George, Minu, Gonzalez, Edgar, Gottschalk, Michael Everett, Guido, Giancarlo, Hassan, Amir Ali, Hershkovitz, Eli, Huerta-Saenz, Lina P, Hwang, Jin Soon, Ibarra Gomez, Jaime Orlando, Irizarry Gonzalez, Lydia, Jain, Nina, Jelley, David H, Kim, Ho-Seong, Kovalenko, Tatiana, Laffel, Lori Michelle B, Leichter, Steven B, Liberatore Jr, Raphael Del Roio, Lynch, Jane, Mahmud, Farid Hussain, Malievskiy, Oleg Arturovich, Muir, Andrew, Nelson, Bryce A, Nevarez Ruiz, Luis Alejandro, Olson, Micah L, Pelayo Orozco, Emilia Susana, Peterkova, Valentina, Ramírez Mendoza, Fernando Ramón, Reddy, Konda Mohan, Rodriguez, Henry, Saenz, Javier Andres, Samoilova, Julia, Schwab, Karl-Otfried, Shah, Sejal H, Shehadeh, Naim, Shoemaker, Ashley H, Skorodok, Yulia, Sobolev, Aleksandr, Solís, Silvana Ernestina, Srinivasan, Shylaja, Tamborlane, William V, Tsalikian, Eva, Valeeva, Farida, Vance, Carl D, Velasquez-Mieyer, Pedro A, Violante Ortiz, Rafael Margarito, Votyakova, Olga, Wei, Haiyan, Weinstock, Ruth S, Wheeler, Mark D, Wicklow, Brandy Alexandra, Willi, Steven M, Wintergerst, Kupper A, Wolf, Risa M, Wood, Jamie Ruth, Yaliwal, Chandan, Yupanqui Lozno, Hernán

“…The incidence of type 2 diabetes in young people is increasing, but treatments remain limited. We aimed to assess the efficacy and safety of an empagliflozin…”
Get full text

156-LB: Assessment of Treatment Patterns in a Real-Life Setting with Dapagliflozin or DPP-4 Inhibitors as Add-On Therapy in Uncontrolled T2DM Patients That Failed on Other Regimens by ESPINOZA-PERALTA, DIEGO, SILVA, ALEJANDRA I., COLLADO, JUAN G., ROGEL-MANZANARES, JORGE D.

“…Mexico is one of the three countries in America with the highest prevalence (14.4%) of DM. Providing medical care to uncontrolled T2DM patients who failed…”
Get full text

130-LB: Retrospective Evaluation of Treatment Patterns in a Real-Life Setting Environment with Dapagliflozin or DPP-4 Inhibitors as Add-On Therapy in Uncontrolled DM2 Patients Who Previously Failed on Other Regimens by ESPINOZA-PERALTA, DIEGO, GONZÁLEZ-CANTÚ, ARNULFO, SILVA, ALEJANDRA I., COLLADO, JUAN G., ROGEL-MANZANARES, JORGE DAVID, HERNÁNDEZ-ALARCÓN, JIMENA H., NORIEGA-MUÑOZ, ANA G.

“…Mexico is one of LatinAmerica countries with the highest prevalence (14.4%) of DM. Medical institutions face the challenge to provide medical care to T2DM…”
Get full text

Progression toward type-2 diabetes mellitus among Mexican pre-diabetics. Assessment of a cohort by Coronado-Malagón, Martín, Gómez-Vargas, J Iván, Espinoza-Peralta, Diego, Arce-Salinas, Alejandro

“…Pre-diabetic Latino subjects have shown higher incidence of type 2 diabetes mellitus (DM2) compared with other populations. The incidence is unknown in the…”
Get full text

Factors associated with microalbuminuria in non-hypertensive type-2 diabetes patients by López-Arce, Gustavo, Espinoza-Peralta, Diego, Hernández-Alarcón, Adriana, Arce-Salinas, C Alejandro

“…Microalbuminuria is a well known risk factor for renal damage and for cardiovascular disease in type-2 diabetic patients. To evaluate anthropometric,…”
Get full text